Tellgen

Tellgen Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Tellgen (300642.SZ) as of Oct 27, 2026 is 65.70. In the previous year, Cash Conversion Cycle (CCC) was 263.23 — a change of -75.04% (lower).

Cash Conversion Cycle

65.70

YoY

-75.04%

Last updated:

Cash Conversion Cycle (CCC) of Tellgen is 2025 65.70 . Cash Conversion Cycle (CCC) of Tellgen was 2024 263.23 . It decreases by -75.04% lower compared to the previous year.

The Tellgen Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
400.70 CNY
Jan 1, 2019
455.22 CNY
Jan 1, 2020
398.65 CNY
Jan 1, 2021
388.51 CNY
Jan 1, 2022
275.17 CNY
Jan 1, 2023
343.17 CNY
Jan 1, 2024
263.23 CNY
Jan 1, 2025
65.70 CNY
The Tellgen Cash Conversion Cycle history
YEARCash Conversion CycleYoY
65.70-75.04%
263.23-23.29%
343.17+24.71%
275.17-29.17%
388.51-2.54%
398.65-12.43%
455.22+13.61%
400.70-15.59%
474.73+4.91%
452.53+66.79%
271.31+9.32%
248.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Cash Conversion Cycle (CCC) of Tellgen is 65.70 in 2025.

Cash Conversion Cycle (CCC) of Tellgen changed from 263.23 to 65.70, representing a -75.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Tellgen since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Tellgen with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Tellgen

All Key Metrics — Tellgen